2025 BIO International Convention
Boston, MA 02210
Event summary
Connect with Cooley and life sciences business leaders at the 2025 BIO International Convention. Cooley is proud to chair the digital health track once again at the annual event.
Featured Cooley sessions
Friday, June 13 – Sunday, June 15 | 8:30 am – 5:45 pm EDT
Advanced Business Development
Advanced Business Development (ABD) is a long-running course focusing on all key aspects of transactions in the biopharma industry. This course is ideal for professionals, ranging from those with limited experience (2 – 3 years) looking to advance their skills to highly experienced dealmakers and executives aiming to hone their skills and network with other dealmakers.
ABD incorporates lectures from experienced dealmakers, reviews example models, dissects actual deals, allows for interaction with other participants and features live Q&A. The course also includes a mock negotiation scenario, where each participant is a member of a deal team assigned to negotiate a transaction involving a drug in development with another team using an actual valuation and deal structuring model.
Cooley partner Kenneth Krisko and special counsel Stephanie Parker Palmer will be instructing this course.
Monday, June 16 | 11:00 am – 12:00 pm EDT (Digital Health)
Investors’ Perspectives – AI and Digital Health Investment Trends in 2025
Join this panel of iconic healthcare and life sciences investors as they share their perspectives on the top areas for artificial intelligence (AI) and digital health investment. Recent reports indicate the number of AI deals in healthcare has grown at twice the rate of AI deals across the tech sector, with one in four dollars invested in healthcare going toward companies leveraging AI. In particular, areas such as patient engagement, clinical decision support, and AI tools for drug discovery and preventative monitoring have shown significant investment traction.
Cooley partner Josh Seidenfeld will moderate this session.
Monday, June 16 | 4:00 – 5:15 pm EDT (Intellectual Property and Legal Landscape)
Intellectual Property Considerations for Inventions Made By, or Involving, Artificial Intelligence
As it has touched so many different areas of human activity, so has AI touched biotechnology and, by extension, biotechnology intellectual property. Panelists will discuss the role of AI in invention, patent eligibility of AI inventions in the US, Europe and China, prosecution of biotech inventions involving AI, and the role of patents in a world of abundance made possible by AI.
Cooley partner Madhuri Roy will speak on this panel.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.